“Marapharm’s focus is on corporate growth and excellence by acquisitions, operations and investments. Marapharm invested in Veritas Pharma Inc. (VRT: CNX) (news releases dated Jan. 9 and Jan. 11, 2017, Marapharm purchased 15 million shares and rights to acquire shares) and to date, this investment has increased substantially in value.
The synergy with Veritas and Marapharm and the development of both company’s products enhances corporate and shareholder value overall. Medical research by Veritas scientists can help to monetize Marapharm’s intellectual properties and products of subsidiaries currently under development. Marapharm, with the assistance of Veritas, intends to advance its cannabis strains. With our unique vertical grow system, yields and quality will be maximized. We think Veritas is a great business model and investment in the cannabis space. Marapharm is the majority owner and largest shareholder of Veritas.” Linda Sampson, Marapharm Ventures Inc. CEO Veritas and or its subsidiary Cannevert Therapeutics Ltd. “Veritas”” have designed and are implementing clinical trials of cannabis strains for pain. Health Canada has granted permission to conduct research. Chemical and animal studies by Veritas have identified suitable strains that warrant immediate human trials which are intended to be implemented this year. The management team consists of veteran academic pharmacologists, anaesthetists and chemists whose commercial mission is to patent its findings in order to sell or license to cancer clinics and pharmaceutical companies, thereby, targeting multi- billion dollar global markets.
Additional Information
In the interest of full disclosure, we call the reader’s attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.
